N. Peacock

发表

P5-13-09: Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2−Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.

J. Hainsworth, C. Hendricks, D. Yardley, 2011 .

A Phase II Trial of DaunoXome, Liposome‐ Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon

D. V. Von Hoff, M. Rothenberg, N. Peacock, 1994, American journal of clinical oncology.

A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors

D. V. Von Hoff, L. Smith, H. Burris, 2004, Investigational New Drugs.

Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors

Suzanne F. Jones, H. Burris, J. Infante, 2012, Cancer investigation.

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

J. Hainsworth, H. Burris, D. Yardley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.

Stephen Szabo, N. Peacock, A. Gu, 2014, Journal of oncology practice.

Biweekly neoadjuvant gemcitabine, epirubicin, and nano-particle albumin bound (nab) paclitaxel (GEA) with tumor SPARC analysis correlated with pathologic responses: Results of a multicenter phase II trial

R. Inhorn, D. Yardley, N. Peacock, 2007 .

A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.

D. V. Von Hoff, T. Petit, P. Ravdin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel in combination with fluorouracil: study design and preliminary results.

D. V. Von Hoff, P. Ravdin, H. Burris, 1997, Oncology.

The lupus anticoagulant-hypoprothrombinemia syndrome

N. Peacock, S. P. Levine, 1994 .

Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).

J. Hainsworth, L. Bosserman, H. Burris, 2012 .

A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.

J. Hainsworth, H. Burris, D. Yardley, 2011, Clinical advances in hematology & oncology : H&O.

Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer

J. Hainsworth, R. Midha, D. Yardley, 2015, Breast Cancer Research and Treatment.

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).

J. Hainsworth, H. Burris, D. Yardley, 2021, Clinical breast cancer.

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)

J. Hainsworth, H. Burris, J. Infante, 2008 .

A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score

J. Hainsworth, H. Burris, C. Hendricks, 2015, Breast Cancer Research and Treatment.

A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.

J. Hainsworth, H. Burris, D. Yardley, 2008, Clinical breast cancer.

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

Suzanne F. Jones, B. Overmoyer, H. Burris, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis

Suzanne F. Jones, J. Hainsworth, G. Chung, 2016 .

A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

J. Hainsworth, D. Yardley, N. Peacock, 2010, Clinical breast cancer.

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

J. Hainsworth, L. Bosserman, J. O’Shaughnessy, 2015, Breast Cancer Research and Treatment.

Patient perspectives on breast cancer treatment plan and summary documents in community oncology care

Anne Moore, J. Griggs, R. Theriault, 2013, Cancer.

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

J. Bendell, N. Peacock, D. Waterhouse, 2016, Cancer investigation.

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

J. Hainsworth, D. Yardley, L. Debusk, 2020, Breast Cancer Research and Treatment.

Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial.

I. Flinn, J. Hainsworth, N. Peacock, 2012 .

Docetaxel (Taxotere) in combination: a step forward.

H. Burris, N. Peacock, S. Fields, 1995, Seminars in oncology.

A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.

Suzanne F. Jones, J. Bendell, H. Burris, 2010 .

Case Report: The Lupus Anticoagulant‐Hypoprothrombinemia Syndrome

N. Peacock, S. P. Levine, 1994, The American journal of the medical sciences.

Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+ patients (pts).

J. Hainsworth, R. Inhorn, D. Yardley, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

J. Hainsworth, H. Burris, R. Inhorn, 2010, Breast Cancer Research and Treatment.

Day 1 pegfilgrastim with dose dense adjuvant chemotherapy: Amelioration of docetaxel neutropenia but not that of doxorubicin/cyclophosphamide. Results from a Sarah Cannon Research Institute pilot study

J. Hainsworth, H. Burris, D. Yardley, 2005 .

Phase II trial of gemcitabine and carboplatin, plus trastuzumab in HER2+ patients as first line therapy in metastatic breast cancer.

J. Hainsworth, D. Yardley, N. Peacock, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).

J. Hainsworth, H. Burris, N. Peacock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.